Rodolfo Montironi


Country: Italy


  1. Montironi R, Cheng L, Scarpelli M, Mazzucchelli R, Lopez Beltran A. How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. Diagn Pathol. 2011;6:31 pubmed publisher
    ..This paper is directed to all who are involved with the application of this classification at the anticancer research, diagnostic, prognostic and therapeutic levels, in particular to uropathologists, urologists and oncologists. ..
  2. Montironi R, Hammond E, Lin D, Gore J, Srigley J, Samaratunga H, et al. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch. 2014;465:623-8 pubmed publisher
    ..These findings need to be reproducible and consistently reported by surgical pathologists. This report highlights the importance of accurate pathology reporting as a critical component of these protocols. ..
  3. Montironi R, Scarpelli M, Galosi A, Lopez Beltran A, Mazzucchelli R, Montorsi F, et al. Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. Hum Pathol. 2014;45:2059-62 pubmed publisher
    ..In particular, this approach avoids the fact that an individual lymph node is oversampled and counted according to number of pieces obtained by the pathologist, mainly in nodes with considerable size. ..
  4. request reprint
    Ciccarese C, Santoni M, Massari F, Modena A, Piva F, Conti A, et al. Metabolic Alterations in Renal and Prostate Cancer. Curr Drug Metab. 2016;17:150-5 pubmed
    ..This review is focused on the metabolic alterations that occur in RCC and PCa and describes the mechanisms underlying such metabolic changes. ..
  5. Conti A, Santoni M, Burattini L, Scarpelli M, Mazzucchelli R, Galosi A, et al. Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World J Urol. 2017;35:517-526 pubmed publisher
    ..In this review, an update on the histopathological evaluation of LND specimens in patients with PCa is given, and focus is made on their clinical and prognostic significance. ..
  6. Santoni M, Scarpelli M, Mazzucchelli R, Lopez Beltran A, Cheng L, Epstein J, et al. Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. Eur Urol. 2016;69:186-90 pubmed publisher
    ..Comprehensive molecular profiling can help identify multiple PCa subtypes and driving alterations. Translating these findings into clinical practice is still challenging. ..
  7. Montironi R, Santoni M, Goteri G, Mazzucchelli R, Lopez Beltran A, Cheng L, et al. Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. Hum Pathol. 2015;46:1040-4 pubmed publisher
    ..The lesion enters in the differential diagnosis with a collision tumor, which has been described rarely in the bladder. ..
  8. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. J Exp Clin Cancer Res. 2015;34:10 pubmed publisher
    ..Our study suggest that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs. ..
  9. Mazzucchelli R, Galosi A, Lopez Beltran A, Scarpelli M, Cheng L, Montironi R. Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. Arch Ital Urol Androl. 2014;86:314-8 pubmed publisher
    ..Repeated biopsy after initial diagnosis of prostate cancer is recommended before inclusion in active surveillance for early detection of significant cancer. ..

More Information


  1. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg C, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10:517-22 pubmed publisher
    ..A better characterization of baseline immunological impairment may optimize the management of this RCC subpopulation. ..
  2. request reprint
    Montironi R, Santoni M, Lopez Beltran A, Cheng L, Moch H, Scarpelli M. Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. Curr Drug Targets. 2015;16:96-102 pubmed
    ..PSMA can serve as target for delivering therapeutic agents such as cytotoxins or radionuclides. ..
  3. Montironi R, Mazzucchelli R, Scarpelli M, Lopez Beltran A, Cheng L. Update on selected renal cell tumors with clear cell features. With emphasis on multilocular cystic clear cell renal cell carcinoma. Histol Histopathol. 2013;28:1555-66 pubmed publisher
    ..In conclusion, recognition of CCRCC and differentiation from other renal cell neoplasms with clear cytoplasm is important not only for prognostication but also for treatment-related reasons. ..
  4. request reprint
    Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol. 2006;37:1137-44 pubmed
    ..This may contribute to a better understanding of the results obtained in screening programs where insignificant cancers are detected along with clinically significant cancers. ..
  5. request reprint
    Montironi R, Mazzucchelli R, Scarpelli M, Lopez Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J Clin Pathol. 2008;61:3-10 pubmed
    ..The WHO 2004 classification is currently used. However, the WHO 1973 classification is still considered by many urologists and oncologists as the international standard in patient management. ..
  6. Montironi R, Scarpelli M, Cheng L, Lopez Beltran A, Burattini M, Kirkali Z, et al. Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol. 2013;64:865-72 pubmed publisher
  7. Montironi R, Scarpelli M, Lopez Beltran A, Mazzucchelli R, Alberts D, Ranger Moore J, et al. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol. 2007;29:47-58 pubmed
  8. request reprint
    Montironi R, Thompson D, Scarpelli M, Mazzucchelli R, Peketi P, Hamilton P, et al. Karyometry detects subvisual differences in chromatin organization state between cribriform and flat high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2004;17:928-37 pubmed
  9. Scalici Gesolfo C, Serretta V, Di Maida F, Giannone G, Barresi E, Franco V, et al. Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). Pathol Res Pract. 2017;213:165-169 pubmed publisher
    ..Due to the clinical behavior of this tumor, in spite of its benign nature, review of the surgical margins and close follow up after partial nephrectomy are mandatory. ..
  10. Raspollini M, Montagnani I, Montironi R, Cheng L, Martignoni G, Minervini A, et al. A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. Pathol Res Pract. 2017;213:804-808 pubmed publisher
    ..This information may assist urologists in developing guidelines for counseling and proper clinical management for patients with "low malignant potential" tumors or small renal masses. ..
  11. Montironi R, Bartels P, Decensi A, Puntoni M, Hurle R, DeCobelli O, et al. A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urol Oncol. 2013;31:557-65 pubmed publisher
    ..This exploratory study establishes that karyometric monitoring can track the results of subtle nuclear changes induced by preventive interventions in men with CaP, thus allowing assessment of agent activity in a cost-effective manner. ..
  12. Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, et al. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). BMC Cancer. 2017;17:493 pubmed publisher
    ..In routine clinical practice the results obtained with VFL seem to be better than the results of the registration trial and reinforce evidence supporting its use after failure of a platinum-based chemotherapy. ..
  13. Montironi R, Cheng L, Mazzucchelli R, Morichetti D, Stramazzotti D, Santinelli A, et al. Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. Cell Oncol. 2008;30:473-82 pubmed
    ..6% of the endothelial cells. With subtypes 3 and 4 the greatest proportion of cells showed a weak intensity (73.5 and 56.4%, respectively). With the subtype 2 and 5 the majority of cells were negative (59.1 and 50.7%, respectively). ..
  14. Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46-57 pubmed publisher
    ..A deep understanding of the metabolic phenotype of bladder cancer will provide novel opportunities for targeted therapeutic strategies. ..
  15. Montironi R, Mazzucchelli R, Lopez Beltran A, Scarpelli M, Cheng L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int. 2011;108:1394-401 pubmed publisher
    ..Some recent studies have suggested that molecular findings associated with HGPIN might be able to predict which men are more likely to have cancer on re-biopsy...
  16. request reprint
    Montironi R, Mazzucchelli R, Lopez Beltran A, Cheng L, Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol. 2007;4:321-32 pubmed
  17. request reprint
    Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Lopez Beltran A, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007;52:1682-9 pubmed
    ..High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated...
  18. Montironi R, Cheng L, Lopez Beltran A, Scarpelli M. Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. Eur Urol Focus. 2017;3:467-469 pubmed publisher
    ..This requires combining and integrating our knowledge of uropathology with that of engineering and informatics. ..